ATE415390T1 - Neue aminopyridinderivate als mglur5-antagonisten - Google Patents
Neue aminopyridinderivate als mglur5-antagonistenInfo
- Publication number
- ATE415390T1 ATE415390T1 AT04717193T AT04717193T ATE415390T1 AT E415390 T1 ATE415390 T1 AT E415390T1 AT 04717193 T AT04717193 T AT 04717193T AT 04717193 T AT04717193 T AT 04717193T AT E415390 T1 ATE415390 T1 AT E415390T1
- Authority
- AT
- Austria
- Prior art keywords
- aminopyridine derivatives
- mglur5 antagonists
- new
- new aminopyridine
- mglur5
- Prior art date
Links
- 150000003927 aminopyridines Chemical class 0.000 title abstract 2
- 101150087728 Grm5 gene Proteins 0.000 title 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000005015 aryl alkynyl group Chemical group 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005312 heteroarylalkynyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0304901A GB0304901D0 (en) | 2003-03-04 | 2003-03-04 | Novel aminopyridine derivatives as mGIuR5 antagonists |
| GB0316430A GB0316430D0 (en) | 2003-07-14 | 2003-07-14 | Aminopyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE415390T1 true ATE415390T1 (de) | 2008-12-15 |
Family
ID=32964064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04717193T ATE415390T1 (de) | 2003-03-04 | 2004-03-04 | Neue aminopyridinderivate als mglur5-antagonisten |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7205411B2 (enExample) |
| EP (2) | EP1603877B1 (enExample) |
| JP (1) | JP2006519251A (enExample) |
| AT (1) | ATE415390T1 (enExample) |
| AU (1) | AU2004218180B2 (enExample) |
| CA (1) | CA2517083A1 (enExample) |
| CY (1) | CY1108837T1 (enExample) |
| DE (1) | DE602004017966D1 (enExample) |
| DK (1) | DK1603877T3 (enExample) |
| ES (1) | ES2316968T3 (enExample) |
| PL (1) | PL1603877T3 (enExample) |
| PT (1) | PT1603877E (enExample) |
| RU (1) | RU2330020C2 (enExample) |
| SI (1) | SI1603877T1 (enExample) |
| UA (1) | UA81464C2 (enExample) |
| WO (1) | WO2004078728A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0413605D0 (en) * | 2004-06-17 | 2004-07-21 | Addex Pharmaceuticals Sa | Novel compounds |
| WO2006115895A2 (en) * | 2005-04-22 | 2006-11-02 | Merck & Co., Inc. | Phenyl ethyne compounds |
| WO2007035823A2 (en) * | 2005-09-20 | 2007-03-29 | Molecular Neuroimaging, Llc | Partial mglur5 antagonists and methods of use thereof |
| DE102005062987A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| MX2009002684A (es) * | 2006-09-11 | 2009-06-05 | Novartis Ag | Derivados de acido nicotinico como moduladores de receptores de glutamato metabotropico. |
| MX2013010698A (es) | 2011-03-18 | 2014-02-17 | Novartis Ag | Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6028963A (ja) * | 1983-07-27 | 1985-02-14 | Takeda Chem Ind Ltd | 置換ビニル誘導体 |
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| DE10009000A1 (de) | 2000-02-25 | 2001-08-30 | Basf Ag | Verfahren zur Herstellung substituierter Indole |
| MXPA03004862A (es) | 2000-12-04 | 2005-02-14 | Hoffmann La Roche | Derivados de feniletenilo o feniletinilo como antagonistas del receptor de glutamato. |
-
2004
- 2004-03-04 CA CA002517083A patent/CA2517083A1/en not_active Abandoned
- 2004-03-04 JP JP2006506343A patent/JP2006519251A/ja active Pending
- 2004-03-04 ES ES04717193T patent/ES2316968T3/es not_active Expired - Lifetime
- 2004-03-04 AT AT04717193T patent/ATE415390T1/de not_active IP Right Cessation
- 2004-03-04 SI SI200431006T patent/SI1603877T1/sl unknown
- 2004-03-04 PT PT04717193T patent/PT1603877E/pt unknown
- 2004-03-04 DK DK04717193T patent/DK1603877T3/da active
- 2004-03-04 EP EP04717193A patent/EP1603877B1/en not_active Expired - Lifetime
- 2004-03-04 EP EP08018437A patent/EP2028180A1/en not_active Withdrawn
- 2004-03-04 RU RU2005130647/04A patent/RU2330020C2/ru not_active IP Right Cessation
- 2004-03-04 WO PCT/IB2004/000745 patent/WO2004078728A1/en not_active Ceased
- 2004-03-04 UA UAA200508498A patent/UA81464C2/xx unknown
- 2004-03-04 DE DE602004017966T patent/DE602004017966D1/de not_active Expired - Lifetime
- 2004-03-04 PL PL04717193T patent/PL1603877T3/pl unknown
- 2004-03-04 AU AU2004218180A patent/AU2004218180B2/en not_active Ceased
-
2005
- 2005-09-02 US US11/225,490 patent/US7205411B2/en not_active Expired - Fee Related
-
2007
- 2007-03-13 US US11/717,860 patent/US20080004316A1/en not_active Abandoned
-
2009
- 2009-02-26 CY CY20091100218T patent/CY1108837T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1108837T1 (el) | 2014-07-02 |
| RU2330020C2 (ru) | 2008-07-27 |
| PL1603877T3 (pl) | 2009-05-29 |
| PT1603877E (pt) | 2009-02-11 |
| ES2316968T3 (es) | 2009-04-16 |
| EP2028180A1 (en) | 2009-02-25 |
| DE602004017966D1 (de) | 2009-01-08 |
| JP2006519251A (ja) | 2006-08-24 |
| DK1603877T3 (da) | 2009-03-09 |
| RU2005130647A (ru) | 2006-04-10 |
| US20060030601A1 (en) | 2006-02-09 |
| US7205411B2 (en) | 2007-04-17 |
| SI1603877T1 (sl) | 2009-04-30 |
| EP1603877A1 (en) | 2005-12-14 |
| AU2004218180B2 (en) | 2009-11-12 |
| US20080004316A1 (en) | 2008-01-03 |
| UA81464C2 (en) | 2008-01-10 |
| WO2004078728A1 (en) | 2004-09-16 |
| CA2517083A1 (en) | 2004-09-16 |
| EP1603877B1 (en) | 2008-11-26 |
| AU2004218180A1 (en) | 2004-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004017213D1 (de) | Allosterische modulatoren von metabotropen glutamatrezeptoren | |
| EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
| SE0303180D0 (sv) | Novel compounds | |
| SE0302232D0 (sv) | Novel Compounds | |
| SE0201635D0 (sv) | Novel compounds | |
| EA200700047A1 (ru) | Новые алкильные производные в качестве метаботропных рецепторов глутамата | |
| DE69328975D1 (de) | Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten | |
| ATE166650T1 (de) | Spiroazacyclischderivate als substanz p antagonisten | |
| ATE318267T1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
| DE602005025672D1 (de) | Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren | |
| CY1111858T1 (el) | Ετεροκυκλικα παραγωγα ως διαμορφωτες υποδοχεα οπιοειδων | |
| ATE444065T1 (de) | 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-deriva e als pde-4-hemmer zur behandlung von neurologischen syndromen | |
| CY1108837T1 (el) | ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5 | |
| DE602005019241D1 (de) | Heterocyclische kondensierte verbindungen und ihre verwendung als antidiuretische mittel | |
| EA200801734A1 (ru) | Производные n-тиазол-2-илбензамида | |
| EA200301143A1 (ru) | Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6 | |
| DE60327375D1 (de) | Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten | |
| BG105710A (en) | 5ht1 antagonists for antidepressant therapy | |
| ATE256678T1 (de) | 4-(2-pyridyl)piperazine als agonisten des 5ht7 rezeptors | |
| EA200401099A1 (ru) | Производные гетероциклического амида | |
| ATE383343T1 (de) | Imidazolderivate verwendbar als histamin h3 rezeptorliganden | |
| ATE283269T1 (de) | 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems | |
| SE0303419D0 (sv) | New use 11 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1603877 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |